Q3 2024 Beam Therapeutics Inc Earnings Call

By Yahoo! Finance | Nov 6, 2024 at 01:46 AM EST

Beam provided updates on their third quarter 2024 business, highlighting data on BEAM-101 for sickle cell disease and ESCAPE technology for gene editing. They are optimistic about the potential impact of their therapies. BEAM-101 clinical data show promising results similar to sickle cell trait.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.